BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 24782337)

  • 1. Identification of a novel de novo deletion in RAF1 associated with biventricular hypertrophy in Noonan syndrome.
    Sana ME; Spitaleri A; Spiliotopoulos D; Pezzoli L; Preda L; Musco G; Ferrazzi P; Iascone M
    Am J Med Genet A; 2014 Aug; 164A(8):2069-73. PubMed ID: 24782337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The novel RAF1 mutation p.(Gly361Ala) located outside the kinase domain of the CR3 region in two patients with Noonan syndrome, including one with a rare brain tumor.
    Harms FL; Alawi M; Amor DJ; Tan TY; Cuturilo G; Lissewski C; Brinkmann J; Schanze D; Kutsche K; Zenker M
    Am J Med Genet A; 2018 Feb; 176(2):470-476. PubMed ID: 29271604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neonatal pulmonary arterial hypertension and Noonan syndrome: two fatal cases with a specific RAF1 mutation.
    Hopper RK; Feinstein JA; Manning MA; Benitz W; Hudgins L
    Am J Med Genet A; 2015 Apr; 167A(4):882-5. PubMed ID: 25706034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A severe clinical phenotype of Noonan syndrome with neonatal hypertrophic cardiomyopathy in the second case worldwide with RAF1 S259Y neomutation.
    Jaouadi H; Chehida AB; Kraoua L; Etchevers HC; Argiro L; Kasdallah N; Blibech S; Delague V; Lévy N; Tebib N; Mrad R; Abdelhak S; Benkhalifa R; Zaffran S
    Genet Res (Camb); 2019 Apr; 101():e6. PubMed ID: 31030682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Noonan syndrome associated with both a new Jnk-activating familial SOS1 and a de novo RAF1 mutations.
    Longoni M; Moncini S; Cisternino M; Morella IM; Ferraiuolo S; Russo S; Mannarino S; Brazzelli V; Coi P; Zippel R; Venturin M; Riva P
    Am J Med Genet A; 2010 Sep; 152A(9):2176-84. PubMed ID: 20683980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclosporine attenuates cardiomyocyte hypertrophy induced by RAF1 mutants in Noonan and LEOPARD syndromes.
    Dhandapany PS; Fabris F; Tonk R; Illaste A; Karakikes I; Sorourian M; Sheng J; Hajjar RJ; Tartaglia M; Sobie EA; Lebeche D; Gelb BD
    J Mol Cell Cardiol; 2011 Jul; 51(1):4-15. PubMed ID: 21440552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PHENOTYPIC CONSEQUENCES AND THE MALIGNANCY RISK IN FAMILIAL NOONAN SYNDROME DUE TO A RARE P.S427G RAF1 MUTATION.
    Pelc M; Ciara E; Jezela-Stanek A; Krajewska-Walasek M
    Genet Couns; 2016; 27(3):325-333. PubMed ID: 30204961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delineation of LZTR1 mutation-positive patients with Noonan syndrome and identification of LZTR1 binding to RAF1-PPP1CB complexes.
    Umeki I; Niihori T; Abe T; Kanno SI; Okamoto N; Mizuno S; Kurosawa K; Nagasaki K; Yoshida M; Ohashi H; Inoue SI; Matsubara Y; Fujiwara I; Kure S; Aoki Y
    Hum Genet; 2019 Jan; 138(1):21-35. PubMed ID: 30368668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impaired binding of 14-3-3 to C-RAF in Noonan syndrome suggests new approaches in diseases with increased Ras signaling.
    Molzan M; Schumacher B; Ottmann C; Baljuls A; Polzien L; Weyand M; Thiel P; Rose R; Rose M; Kuhenne P; Kaiser M; Rapp UR; Kuhlmann J; Ottmann C
    Mol Cell Biol; 2010 Oct; 30(19):4698-711. PubMed ID: 20679480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RAF1-associated Noonan syndrome presenting antenatally with an abnormality of skull shape, subdural haematoma and associated with novel cerebral malformations.
    Hartill VL; Dillon MW; Warren DJ; Blyth M
    Clin Dysmorphol; 2017 Apr; 26(2):101-106. PubMed ID: 27753652
    [No Abstract]   [Full Text] [Related]  

  • 11. Molecular and clinical analysis of RAF1 in Noonan syndrome and related disorders: dephosphorylation of serine 259 as the essential mechanism for mutant activation.
    Kobayashi T; Aoki Y; Niihori T; Cavé H; Verloes A; Okamoto N; Kawame H; Fujiwara I; Takada F; Ohata T; Sakazume S; Ando T; Nakagawa N; Lapunzina P; Meneses AG; Gillessen-Kaesbach G; Wieczorek D; Kurosawa K; Mizuno S; Ohashi H; David A; Philip N; Guliyeva A; Narumi Y; Kure S; Tsuchiya S; Matsubara Y
    Hum Mutat; 2010 Mar; 31(3):284-94. PubMed ID: 20052757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Germline gain-of-function mutations in RAF1 cause Noonan syndrome.
    Razzaque MA; Nishizawa T; Komoike Y; Yagi H; Furutani M; Amo R; Kamisago M; Momma K; Katayama H; Nakagawa M; Fujiwara Y; Matsushima M; Mizuno K; Tokuyama M; Hirota H; Muneuchi J; Higashinakagawa T; Matsuoka R
    Nat Genet; 2007 Aug; 39(8):1013-7. PubMed ID: 17603482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy.
    Pandit B; Sarkozy A; Pennacchio LA; Carta C; Oishi K; Martinelli S; Pogna EA; Schackwitz W; Ustaszewska A; Landstrom A; Bos JM; Ommen SR; Esposito G; Lepri F; Faul C; Mundel P; López Siguero JP; Tenconi R; Selicorni A; Rossi C; Mazzanti L; Torrente I; Marino B; Digilio MC; Zampino G; Ackerman MJ; Dallapiccola B; Tartaglia M; Gelb BD
    Nat Genet; 2007 Aug; 39(8):1007-12. PubMed ID: 17603483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and molecular characterization of children with Noonan syndrome and other RASopathies in Argentina.
    Chinton J; Huckstadt V; Moresco A; Gravina LP; Obregon MG
    Arch Argent Pediatr; 2019 Oct; 117(5):330-337. PubMed ID: 31560489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prenatal diagnosis of hypoplastic left heart syndrome associated with Noonan Syndrome and de novo RAF1 mutation.
    Schulz S; Fröber R; Kraus C; Schneider U
    Prenat Diagn; 2012 Oct; 32(10):1016-8. PubMed ID: 22821648
    [No Abstract]   [Full Text] [Related]  

  • 16. Cellular interplay via cytokine hierarchy causes pathological cardiac hypertrophy in RAF1-mutant Noonan syndrome.
    Yin JC; Platt MJ; Tian X; Wu X; Backx PH; Simpson JA; Araki T; Neel BG
    Nat Commun; 2017 May; 8():15518. PubMed ID: 28548091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RSK3 is required for concentric myocyte hypertrophy in an activated Raf1 model for Noonan syndrome.
    Passariello CL; Martinez EC; Thakur H; Cesareo M; Li J; Kapiloff MS
    J Mol Cell Cardiol; 2016 Apr; 93():98-105. PubMed ID: 26940993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased BRAF heterodimerization is the common pathogenic mechanism for noonan syndrome-associated RAF1 mutants.
    Wu X; Yin J; Simpson J; Kim KH; Gu S; Hong JH; Bayliss P; Backx PH; Neel BG; Araki T
    Mol Cell Biol; 2012 Oct; 32(19):3872-90. PubMed ID: 22826437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RAF1 mutation leading to hypertrophic cardiomyopathy in a Chinese family with a history of sudden cardiac death: A diagnostic insight into Noonan syndrome.
    Zheng J; Peng L; Cheng R; Li Z; Xie J; Huang E; Cheng J; Zhao Q
    Mol Genet Genomic Med; 2024 Jan; 12(1):e2290. PubMed ID: 37787490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A boy with Burkitt lymphoma associated with Noonan syndrome due to a mutation in RAF1.
    Cianci P; Tono V; Sala A; Locatelli L; Carta C; Rizzari C; Biondi A; Selicorni A
    Am J Med Genet A; 2013 Jun; 161A(6):1401-4. PubMed ID: 23613113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.